Researchers found that tumor necrosis factor inhibitors failed to lower acute coronary syndrome risk among patients with early rheumatoid arthritis enrolled in Sweden's national registry from 1999 to 2007. The anti-TNF drugs did not reduce ACS risk even among patients who responded well to the drugs at three months. The study appears in Arthritis & Rheumatism.
TNF inhibitors don't cut ACS risk in arthritis patients
SmartBrief Job Listings for Health Care